4 citations
,
December 2024 in “European Journal of Medicinal Chemistry” New pyrazole-based inhibitors show promise for treating metabolic diseases and other conditions.
61 citations
,
December 1994 in “Planta”
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
18 citations
,
December 2016 in “European journal of pharmacology” A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.
28 citations
,
December 2001 in “European Journal of Pharmacology” M50054 may help treat hepatitis and hair loss from chemotherapy.
July 2022 in “Journal of Investigative Dermatology” Blocking DPP4 can help activate hair growth and improve hair regeneration.
December 2025 in “Biomolecules” Compound 7p shows strong potential as an anticancer agent.
6 citations
,
August 2013 in “한국응용생명화학회지” Certain natural compounds can block an enzyme linked to prostate enlargement and hair loss, showing potential for new treatments.
July 2024 in “Journal of Investigative Dermatology” Inhibiting PDE8A may help treat hair loss by boosting fat cell growth and hair regeneration.
6 citations
,
February 2023 in “Journal of nanobiotechnology” The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Blocking a key energy pathway in human hair follicles can trigger stress responses that stop cell growth.
1 citations
,
January 2020 in “Seoul National University Open Repository (Seoul National University)” PDE3 inhibitor may help treat hair loss by promoting hair growth.
2 citations
,
February 2004 in “Biopolymers” 4-(4-Phenoxybenzoyl)benzoic acid derivatives can both increase and decrease certain types of reactive oxygen species, and may be relevant to hair loss.
1 citations
,
January 2002 in “PubMed” PM-9, like finasteride, may help treat certain diseases by blocking a key enzyme.
60 citations
,
January 2004 in “The journal of investigative dermatology/Journal of investigative dermatology” Applying a specific inhibitor lightens skin and hair color.
20 citations
,
January 2003 in “Chemical and Pharmaceutical Bulletin” The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
10 citations
,
November 2017 in “Letters in drug design & discovery” Researchers identified promising inhibitors for the BRD4 protein, including finasteride and amentoflavone.
136 citations
,
April 2013 in “Clinical Cancer Research” The drug IPI-926 is safe at 160 mg daily and may help treat certain tumors, especially basal cell carcinoma.
May 2023 in “Journal of Investigative Dermatology” Blocking DPP4 can potentially speed up hair growth and regeneration, especially after injury or in cases of hair loss.
April 2023 in “Medicina Clínica (english Edition)”
25 citations
,
January 2017 in “Steroids” Allopregnanolone increases growth and changes gene activity in human brain cancer cells.
22 citations
,
March 2003 in “Steroids” PM-9 and finasteride effectively inhibit the enzyme that converts testosterone to DHT.
1 citations
,
November 2022 in “Journal of Investigative Dermatology” ALRN-6924 may prevent hair loss caused by chemotherapy.
January 2005 in “Urologia Journal” 5αR inhibitors help slow early prostate cancer cell growth, suggesting combined treatments are needed.
3 citations
,
June 2018 in “Bioorganic & medicinal chemistry” Compounds 4, 4b, and 4c effectively inhibit an enzyme linked to testosterone conversion without significant toxicity.
March 1998 in “Journal of dermatological science” Diphencyprone initially increases mouse hair growth, then slows it, possibly due to changes in specific protein levels.
April 2017 in “Journal of Investigative Dermatology” HPH-15, a new compound, effectively reduces skin fibrosis in experiments without causing harm.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
July 2024 in “Journal of Investigative Dermatology” PH-762 shows promise in treating skin cancer by effectively targeting and silencing PD-1 in tumors with minimal side effects.